These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1584 related articles for article (PubMed ID: 32540904)

  • 21. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
    Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J
    Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization.
    Ding S; Laumaea A; Benlarbi M; Beaudoin-Bussières G; Gasser R; Medjahed H; Pancera M; Stamatatos L; McGuire AT; Bazin R; Finzi A
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33114742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
    Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY
    mBio; 2020 Sep; 11(5):. PubMed ID: 32978311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
    Zhou D; Duyvesteyn HME; Chen CP; Huang CG; Chen TH; Shih SR; Lin YC; Cheng CY; Cheng SH; Huang YC; Lin TY; Ma C; Huo J; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Donat RF; Godwin K; Buttigieg KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll MW; Gilbert-Jaramillo J; Knight ML; James W; Owens RJ; Naismith JH; Townsend AR; Fry EE; Zhao Y; Ren J; Stuart DI; Huang KA
    Nat Struct Mol Biol; 2020 Oct; 27(10):950-958. PubMed ID: 32737466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.
    Tai W; Zhang X; Drelich A; Shi J; Hsu JC; Luchsinger L; Hillyer CD; Tseng CK; Jiang S; Du L
    Cell Res; 2020 Oct; 30(10):932-935. PubMed ID: 32759966
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.
    Long SW; Olsen RJ; Christensen PA; Bernard DW; Davis JJ; Shukla M; Nguyen M; Saavedra MO; Yerramilli P; Pruitt L; Subedi S; Kuo HC; Hendrickson H; Eskandari G; Nguyen HAT; Long JH; Kumaraswami M; Goike J; Boutz D; Gollihar J; McLellan JS; Chou CW; Javanmardi K; Finkelstein IJ; Musser JM
    mBio; 2020 Oct; 11(6):. PubMed ID: 33127862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
    Lv H; Wu NC; Tsang OT; Yuan M; Perera RAPM; Leung WS; So RTY; Chan JMC; Yip GK; Chik TSH; Wang Y; Choi CYC; Lin Y; Ng WW; Zhao J; Poon LLM; Peiris JSM; Wilson IA; Mok CKP
    Cell Rep; 2020 Jun; 31(9):107725. PubMed ID: 32426212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease.
    Wang P; Liu L; Nair MS; Yin MT; Luo Y; Wang Q; Yuan T; Mori K; Solis AG; Yamashita M; Garg A; Purpura LJ; Laracy JC; Yu J; Joshua-Tor L; Sodroski J; Huang Y; Ho DD
    Emerg Microbes Infect; 2020 Dec; 9(1):2091-2093. PubMed ID: 32930052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A human monoclonal antibody blocking SARS-CoV-2 infection.
    Wang C; Li W; Drabek D; Okba NMA; van Haperen R; Osterhaus ADME; van Kuppeveld FJM; Haagmans BL; Grosveld F; Bosch BJ
    Nat Commun; 2020 May; 11(1):2251. PubMed ID: 32366817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
    Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
    Tortorici MA; Beltramello M; Lempp FA; Pinto D; Dang HV; Rosen LE; McCallum M; Bowen J; Minola A; Jaconi S; Zatta F; De Marco A; Guarino B; Bianchi S; Lauron EJ; Tucker H; Zhou J; Peter A; Havenar-Daughton C; Wojcechowskyj JA; Case JB; Chen RE; Kaiser H; Montiel-Ruiz M; Meury M; Czudnochowski N; Spreafico R; Dillen J; Ng C; Sprugasci N; Culap K; Benigni F; Abdelnabi R; Foo SC; Schmid MA; Cameroni E; Riva A; Gabrieli A; Galli M; Pizzuto MS; Neyts J; Diamond MS; Virgin HW; Snell G; Corti D; Fink K; Veesler D
    Science; 2020 Nov; 370(6519):950-957. PubMed ID: 32972994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing a low-cost and accessible COVID-19 vaccine for global health.
    Hotez PJ; Bottazzi ME
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008548. PubMed ID: 32726304
    [No Abstract]   [Full Text] [Related]  

  • 36. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
    Hurlburt NK; Seydoux E; Wan YH; Edara VV; Stuart AB; Feng J; Suthar MS; McGuire AT; Stamatatos L; Pancera M
    Nat Commun; 2020 Oct; 11(1):5413. PubMed ID: 33110068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A spike with which to beat COVID-19?
    Alam N; Higgins MK
    Nat Rev Microbiol; 2020 Aug; 18(8):414. PubMed ID: 32415242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions.
    Gavor E; Choong YK; Er SY; Sivaraman H; Sivaraman J
    Trends Immunol; 2020 Nov; 41(11):1006-1022. PubMed ID: 33041212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.